In 2017, the financial report of Chongqing Huasen came, with a net profit of 100 million yuan attributable to the parent company

1、 Yesterday (February 26), Chongqing Huasen Pharmaceutical Co., Ltd (hereinafter referred to as Chongqing Huasen) announced the 2017 annual performance express In 2017, the company realized operating revenue of 592095500 yuan, an increase of 7.33% over the same period of last year; operating profit of 129855100 yuan, an increase of 38.69% over the same period of last year; total profit of 131.3235 million yuan, an increase of 15.75% over the same period of last year; net profit attributable to shareholders of listed companies of 110.9975 million yuan, an increase of 15.98% over the same period of last year (as shown in the figure below) Figure 1 In October 2017, Chongqing Huasen was listed on the small and medium-sized board of Shenzhen Stock Exchange, becoming the 50th listed company in Chongqing After years of continuous development, Huasen pharmaceutical has successfully entered the A-share market in 2017 and ushered in its golden development period From 2014 to 2017, the operating revenue and net profit level of Huasen pharmaceutical continued to increase rapidly (as shown in Figure 2), with a year-on-year growth rate of 25.67%, 29.62% and 15.98% respectively In 2017, it achieved a gratifying performance of more than 100 million profits Figure 2 Profits of parent company of Huasen pharmaceutical in 2014-2017 2 Market situation of Chongqing Huasen Pharmaceutical Co., Ltd Huasen Pharmaceutical Co., Ltd is a national key high-tech enterprise focusing on research and development, production and sales of proprietary drugs and chemical drugs The company's products cover a wide range of drug use areas According to the bidding information query database of Yaozhi, 35 drugs of Chongqing Huasen have won the bidding in 30 regions, of which the highest price is 0.12g orlistat capsule, and the bidding price is 259.13 yuan (as shown in Figure 3) In addition, the main products on the market are Changshong (polyethylene glycol 4000 powder), Duliang soft capsule, spirulina capsule, weidemei (magnesium aluminate tablet), Ganju Bingmei tablet, etc (as shown in Figure 4), among which the exclusive drugs include tongxieling granule, Ganju Bingmei tablet, Duliang soft capsule, Liuwei Anshen capsule, Bawei Qilong granule, which are the key products or potential products of Huasen pharmaceutical Strong products, good market sales Figure 3 Bidding situation of Chongqing Huasen Pharmaceutical Co., Ltd Figure 4 Top 20 bidding varieties of Chongqing Huasen Pharmaceutical Co., Ltd in addition, from recent years, we can see that since 2007, the number of winning drugs of Huasen has continued to rise, with small fluctuations in the middle, reaching the highest in 2016, and the number of winning drugs in 2017 is relatively large It can be seen that the market trend of Huasen medicine is good, and it is worth looking forward to in the future Figure 5 The number of winning varieties in 2007-2017 III The registration of Chongqing Huasen pharmaceutical 1 The overall distribution of Chongqing Huasen pharmaceutical registration during 2003-2017, the number of drugs declared and approved by Huasen pharmaceutical fluctuated, with the largest number of drugs declared and approved in 2004 There will be a decrease in the follow-up, but there will be a small peak in 2009 and 2014, and there will be a significant increase in 2017 It is expected that the drug layout of Watson 2018 will continue to rise Fig 6 declaration and approval of Huasen from 2003 to 2017 2 The type of drugs declared by Chongqing Huasen can be seen from Fig 7 There are 17 new drugs (calculated by acceptance number, the same below), including 7 traditional Chinese medicine and 10 chemical drugs Three new drugs are approved for clinical use and seven for production (as shown in Figure 8) Figure 7 application and approval of Chongqing Huasen in 2003-2017 figure 8 Application and approval of Chongqing Huasen new drug In addition, Chongqing Huasen also applied for 10 generic drugs, among which cilostazol, sodium ferulate for injection, Troxerutin Injection, diammonium glycyrrhizinate and sodium ferulate have been approved for production, esomeprazole sodium for injection and penehyclidine hydrochloride injection are still under review and approval Figure 9 application and approval of Chongqing Huasen generic medicine 3 The main application fields of Chongqing Huasen pharmaceutical are digestive tract and metabolism, blood and hematopoietic organs, cardiovascular system, nervous system and respiratory system Among them, weidemai (magnesium aluminate tablet), the gastrointestinal medicine for digestive tract and metabolic system, is its star product, and also its gold selling brand medicine, while the same other large treatment fields also have their potential brands that have been active in the market After the successful listing in 2017, we will focus on several major areas, deepen our efforts in advantageous products, develop new potential products, and move towards a new year with different characteristics Figure 10 application for drug treatment by Chongqing Huasen